Latest Xeltis News
Xeltis appoints new Chief Medical Officer
Laura Monti2020-10-01T11:26:11+00:00October 1st, 2020|Latest News|
Jochen Reinöhl joins Xeltis as Chief Medical Officer, bringing to the company extensive experience in medical affairs from his previous role at Edwards Lifesciences. Prior to his corporate career, he worked for over ten [...]
Xeltis joins prestigious research network ArtMoMa
Laura Monti2020-05-12T13:05:47+00:00May 12th, 2020|Latest News|
Xeltis is among seven European companies selected to join the prestigious research network ArtMoMa. The program aims to reach new heights in the emerging field of artificial molecular machines, including supramolecular technology. ArtMoMa is built [...]
Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern
Laura Monti2020-02-26T22:51:37+00:00February 25th, 2020|Latest News|
Deutsche - Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve patients’ lives at the Spirit of Bern conference on 27th February. The [...]
Xeltis trials show promising function of living heart valves restored in children
Laura Monti2020-02-14T11:59:54+00:00February 14th, 2020|Latest News|
For more on the data, please click here CEO announced continuation of the clinical trial program for the pulmonary valve in EU, Asia and USA Clinical trial results of Xeltis pulmonary valve (PV) show promising [...]
Xeltis’ closes €10.5 million Series D financing
Laura Monti2019-09-05T11:33:20+00:00September 5th, 2019|Latest News|
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The funding was provided by existing institutional and private investors, including all venture capital funds [...]
Xeltis preclinical data extend potential of restorative approach to small diameter vessels
admin2019-07-02T10:20:07+00:00July 2nd, 2019|Latest News|
Positive preclinical results from the three different applications of Xeltis’ restorative small diameter blood vessels have been presented at 2019 International Symposium for Applied Cardiovascular Biology and Vascular Tissue Engineering in Zurich (CH). All [...]
Xeltis’ restorative technology at Biomaterials
admin2019-06-11T12:52:57+00:00April 3rd, 2019|Latest News|
Preclinical data on Xeltis’ restorative heart valves will illustrate supramolecular materials’ potential application in clinical practice at the Society for Biomaterials annual meeting on Thursday 4 April. Xeltis CTO Martijn Cox will present 2-year [...]
Xeltis’ CEO shares cardiovascular strategy at Biocapital
admin2019-06-11T12:57:22+00:00March 14th, 2019|Latest News|
A cardiovascular strategy to best leverage the potential of its RestoreX™ technology platform has been shared by Xeltis CEO Eliane Schutte at Biocapital Europe meeting in Amsterdam today. The company is moving forward with [...]